ERBB2 and breast carcinoma: There is currently one ongoing phase 2 trial testing a combination with chemotherapy, trastuzumab or endocrine therapy in HER-2-positive or HER-2-low/hormonal receptor-positive breast cancer patients (NCT03321981).